Can eribulin change the treatment algorithm in the management of breast cancer?. (July 2013)

• Record Type: Journal Article
• Authors: Mirshahidi, Hamid R; Mirshahidi, Saied; Abraham, Jame
• Is Part Of: Breast cancer management. Volume 2:Number 4(2013)
• Page Start: 339
• Page End: 346
• Publication Date: 2013-07
• Subjects: Breast -- Cancer -- Periodicals; Breast -- Cancer -- Treatment -- Periodicals; 616.9944905
• DOI: 10.2217/bmt.13.31
• Languages: English
• ISSNs: 1758-1923

Abstract

SUMMARY The US FDA approved eribulin as a third-line treatment for patients with metastatic breast cancer on 15 November 2010, based on the EMBRACE study. Eribulin has modified the management and enriched therapeutic options for patients with metastatic breast cancer. It has also improved life expectancy without increasing toxicity in this group of patients. In the future, this agent may achieve additional indications for treating malignancies other than breast cancer. This article summarizes data from various eribulin studies.